Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer

Fig. 1

MCI-715 is a potent inhibitor of ABCC3 and its application significantly reduces PDAC cell growth. a Western blot probed with anti-ABCC3 antibody (C-18; Santa Cruz) confirming the overexpression of ABCC3 in transfected cells. Lane 1, whole cell lysate prepared from untransfected HEK293T; lane 2, whole cell lysate prepared from HEK293T cells transiently-transfected with pcDNA3.1-ABCC3. b ABCC3 effluxes Calcein-AM to reduce accumulation in HEK293T cells (left histogram). Flow cytometry histogram comparing Calcein accumulation in red-fluorescent dsRed-expressing HEK293T cells co-transfected with pcDNA3-ABCC3 (red trace) compared to non-expressing cells (blue trace). c ABCC3 is fully inhibited by 750 μM MCI-715 (right histogram; colour coding as before). d MCI-715 is a more potent inhibitor of calcein-AM efflux by ABCC3 than sulindac sulphide. IC50 data are presented as mean ± SEM of 3 independent experiments, statistical analysis was performed by unpaired Student’s t-test p = 0.0033; The effect of the treatment of indicated PDAC cell lines with increasing doses of MCI-715 on anchorage-dependent e and anchorage-independent f cell growth. PDAC cells were treated with indicated doses of MCI-715 and number of cells was assessed after 72 h. For the assessment of anchorage-independent growth, cells were plated on soft agar, treated with indicated concentrations of MCI-715 and number of colonies was counted after 4 weeks. Data is expressed as fold change of cells treated with vehicle (DMSO). All experiments are presented as mean ± SEM of 3 independent experiments. One-way ANOVA was used for statistical analysis, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page